The Discounted Cash Flow (DCF) valuation of ReShape Lifesciences Inc (RSLS) is (23.90) USD. With the latest stock price at 6.05 USD, the upside of ReShape Lifesciences Inc based on DCF is -495.0%.
Based on the latest price of 6.05 USD and our DCF valuation, ReShape Lifesciences Inc (RSLS) is a sell. selling RSLS stocks now will result in a potential gain of 495.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.9% - 9.9% | 8.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (52.55) - (15.88) | (23.90) |
| Upside | -968.7% - -362.4% | -495.0% |